Use the labels in the right column to find what you want. Or you can go thru them one by one, there are only 32,8g21 posts. Searching is done in the search box in upper left corner. I blog on anything to do with stroke. DO NOT DO ANYTHING SUGGESTED HERE AS I AM NOT MEDICALLY TRAINED, YOUR DOCTOR IS, LISTEN TO THEM. BUT I BET THEY DON'T KNOW HOW TO GET YOU 100% RECOVERED. I DON'T EITHER BUT HAVE PLENTY OF QUESTIONS FOR YOUR DOCTOR TO ANSWER.
Tuesday, April 21, 2026
Gut-brain axis targeting postbiotics for treatment of psychological and neurodegenerative disorders
There is massive amounts of research on this already! What's needed IS EXACT PROTOCOLS TO GET SURVIVORS RECOVERED! And you are too blitheringly stupid to see what needs to be done!
Postbiotics offer a therapeutic option as an adjuvant or alternative therapy.
•
Stringent manufacturing, handling and storage requirements plaguing probiotics are circumvented by postbiotics.
•
Postbiotics can alter neurogenetics and trigger meaningful changes to psychological and neurodegenerative pathways.
•
Stress hormonal responses are altered by postbiotics, mitigating pathogenesis of anxiety and depression.
Abstract
Current pharmacological treatments for psychological and neurodegenerative disorders largely ignore the vital role of the gut microbiome in cognition. Antipsychotics and antidepressants often disturb the gut environment, impacting mood stabilisation, neurotransmitter signalling, and cognitive functions mediated by the gut-brain axis. This ultimately undermines treatment efficacy while triggering cascading metabolic side effects, including weight gain and hyperglycaemia. Coupled with the rising global burden of these disorders, there is a need for innovative therapies that effectively target the gut microbiome to pharmacologically mediate the gut-brain axis. Postbiotics, comprising inert microorganisms or their components, are one such microbiome-targeted therapy that has recently shown the capacity to treat an array of psychological and neurodegenerative disorders, including depression, anxiety, Alzheimer's, and Parkinson's disease, while mitigating common manufacturing, storage, and efficacy limitations of conventional probiotics. However, clinical trials validating postbiotic treatment efficacy in neurological diseases are lacking, indicating the need for further investigation. This review therefore aims to examine the therapeutic potential of postbiotics and bridge the gap between preclinical research and clinical practice.
No comments:
Post a Comment